TP53 Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease

BACKGROUND: The TP53 signature that predicts the mutation status of TP53 has been shown to be a prognostic factor and predictor of neoadjuvant chemotherapy (NAC) response. OBJECTIVES: The current study sought to investigate the utility of the TP53 signature for predicting pathological complete respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Shin, Sasaki, Keiju, Ishioka, Chikashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170595/
https://www.ncbi.nlm.nih.gov/pubmed/37181950
http://dx.doi.org/10.1177/11782234231167655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170595/
https://www.ncbi.nlm.nih.gov/pubmed/37181950
http://dx.doi.org/10.1177/11782234231167655

Ejemplares similares